PD-1-IN-17 (TFA)

• UNSPSC Description:

  PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-in-17-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC[C@@H](C(O)=O)NC(N[C@H](C1=NN=C([C@@H](N)[C@H](O)C)O1)CCC(N)=O)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  488.37

• References & Citations:

  [1]Pottayil Govindan Nair Sasikumar, et al. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015033301A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported